Research Area Affiliations
Dr. Daniel Faden’s research examines how acquired genomic alterations and viral infection effect head and neck cancer initiation, growth, and response to treatment. As a practicing head and neck cancer surgeon, the overarching goal of his research is to translate findings from the laboratory to clinical advancements that address the most pressing problems faced by head and neck cancer patients.
His efforts are centered on two overlapping arenas:
Understanding mutation acquisition and host-viral interactions in human papilloma virus (HPV)-associated head and neck cancer
A subset of head and neck cancers are caused by viral infection, including HPV. HPV-associated cancers behave differently than non-virally-associated head and neck cancers and are increasing in prevalence, surpassing cervical cancer as the most common HPV-associated malignancy in the U.S. Despite this, little is known regarding how HPV-associated head and neck cancers go from a cell that has become infected with HPV to a full-fledged cancer. Dr. Faden’s research aims to elucidate this process, including how HPV leads to host mutations and how features specific to the virus dictate the behavior of the tumor. Understanding this process is vital for improved diagnostics and treatment decision-making.
Defining how the genomic and immunogenomic landscape of head and neck cancers affects tumor behavior and treatment response
In recent years there has been a rapid accumulation of information regarding the genomic landscape of head and neck cancer. We now know that head and neck cancers possess a complex array of genomic and transcriptomic alterations and largely lack recurrent targetable mutations. In part because of this diversity, we have not yet seen the marked increase in knowledge translate to measurable improvements in patient care. Dr. Faden’s research is focused on understanding how these various acquired alterations impact tumor behavior and treatment response. To do so, he is studying unique and tightly curated head and neck cancer cohorts to help distinguish meaningful signatures from noise.
Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke. Li R, Faden DL, Fakhry C, Langelier C, Jiao Y, Wang Y, Wilkerson MD, Pedamallu CS, Old M, Lang J, Loyo M, Ahn SM, Tan M, Gooi Z, Chan J, Richmon J, Wood LD, Hruban RH, Bishop J, Westra WH, Chung CH, Califano J, Gourin CG, Bettegowda C, Meyerson M, Papadopoulos N, Kinzler KW, Vogelstein B, DeRisi JL, Koch WM, Agrawal N. Head Neck. 2015 Nov;37(11):1642–9.
Targeted next-generation sequencing of TP53 in oral tongue carcinoma from non-smokers. Faden DL, Arron ST, Heaton CM, DeRisi J, South AP, Wang SJ. J Otolaryngol Head Neck Surg. 2016 Sep 17;45(1):47.
Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. Faden DL, Algazi A. J Natl Cancer Inst. 2016 Sep 26;109(1).
Whole exome sequencing of growing and non-growing cutaneous neurofibromas from a single patient with Neurofibromatosis Type 1. Faden DL, Asthana S, Tihan T, DeRisi J, Kliot M. PLoS One. 2017 Jan 18;12(1):e0170348.
Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma. Faden DL, Thomas S, Cantalupo PG, Agrawal N, Myers J, DeRisi J. Oral Oncol. 2017 Nov;74:8–14.
View a complete list of publications on pubmed.gov »